Stoke Therapeutics

63 articles with Stoke Therapeutics

• Stoke Therapeutics to Present at the UBS Global Healthcare Virtual Conference

  5/18/2021

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the UBS Global Healthcare Virtual Conference on Monday, May 24, 2021, at 5:00 p.m. ET.

• Stoke Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates

  5/10/2021

  Stoke Therapeutics, Inc., a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, reported financial results for the first quarter of 2021 and provided business updates.

• Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

  5/4/2021

  Stoke Therapeutics Presents New Data That Demonstrate Tango Antisense Oligonucleotides (ASOs) Increase OPA1 Protein Production and Improve Mitochondrial Function in Cells Derived From Patients With Autosomal Dominant Optic Atrophy (ADOA)

• Stoke Therapeutics Announces MHRA Authorization to Initiate Phase 1/2a Clinical Trial of STK-001 for Dravet Syndrome in the United Kingdom

  3/30/2021

  – New ADMIRAL study complements ongoing U.S. studies and marks first step in global expansion of clinical development of STK-001 – – Study will evaluate safety and PK of multiple doses of STK-001 starting at 30mg; Enrollment and dosing anticipated to begin in 2H 2021 – – STK-001 has the potential to be the first disease-modifying therapy to address the root cause of Dravet syndrome, a severe and progressive genetic epilepsy –

• Stoke Therapeutics to Present at Upcoming Investor Conferences

  3/24/2021

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at two upcoming investor conferences, which will each be conducted in a fireside chat format:

• Stoke Therapeutics Reports Full Year 2020 Financial Results and Provides Business Updates

  3/9/2021

  – First patient dosed in the multiple ascending dose portion of Phase 1/2a MONARCH study of STK-001 in Dravet syndrome – – Preliminary safety and PK data from the single ascending dose portion of MONARCH still expected in H2 2021 – – As of December 31, 2020, Company had $287.5 million in cash, cash equivalents and restricted cash, anticipated to fund operations into 2024 –

• Stoke Therapeutics to Present at the Barclays Global Healthcare Conference

  3/4/2021

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by up-regulating protein expression with RNA-based medicines, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Barclays Global Healthcare Conference on Thursday, March 11, 2021, at 3:35 p.m. ET.

• Stoke Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference

  1/4/2021

  Stoke Therapeutics to Present at the 39 th Annual J.P. Morgan Healthcare Conference

• Stoke Therapeutics to Present at the Needham Virtual Epilepsy & Pain – Specialty CNS Therapeutics Conference

  12/4/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the Needham Virtual Epilepsy & Pain – Specialty Therapeutics Conference

• Stoke Therapeutics Announces Presentations Related to the Company’s Work to Advance STK-001, the First Potential New Medicine to Target the Underlying Cause of Dravet Syndrome at the American Epilepsy Society (AES) 2020 Annual Meeting

  12/4/2020

  – Baseline data from the BUTTERFLY observational study provide initial validation of standard measures of cognition (BSID-III and WPPSI-IV) for use in evaluating non-seizure comorbidities in people with Dravet syndrome – – The current design for the ongoing MONARCH Phase 1/2a study to assess both single and multiple ascending doses of STK-001 in children and adolescents with Dravet syndrome will be presented –

• Stoke Therapeutics Announces Presentations Related to the Company’s Work in Dravet Syndrome at the American Epilepsy Society 2020 Virtual Annual Meeting

  11/25/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that four abstracts related to the Company’s work in Dravet syndrome have been selected for presentation at the upcoming American Epilepsy Society (AES) 2020 Virtual Annual Meeting

• Stoke Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

  11/24/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the closing of its underwritten public offering of 2,875,000 shares of its common stock, including 375,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares,

• Stoke Therapeutics Announces Pricing of $97.5 Million Public Offering

  11/20/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public of $39.00 per share.

• Stoke Therapeutics Announces Proposed Public Offering

  11/18/2020

  Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced a proposed underwritten public offering in which it intends to offer and sell, subject to market and other conditions, up to 2,500,000 shares of its common stock

• Stoke Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference

  11/9/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Stifel 2020 Virtual Healthcare Conference on Monday, November 16, 2020, at 3:20 p.m. ET. A live audio webcast of the presentation will b

• Stoke Therapeutics to Present at 29th Annual Credit Suisse Virtual Healthcare Conference

  11/2/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a clinical-stage biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will participate in a fireside chat at the 29th Annual Credit Suisse Vi

• Stoke Therapeutics Announces Plans to Move Forward With Dosing of STK-001 in Children and Adolescents in its Ongoing Phase 1/2a MONARCH Study for Dravet Syndrome

  10/7/2020

  New Preclinical Repeat-Dose Data Support Company Plans to Evaluate Multiple Ascending Dose Levels in MONARCH, Subject to FDA Review

• Stoke Therapeutics to Present at Cantor Virtual Global Healthcare Conference

  9/9/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that Chief Executive Officer Edward M. Kaye, M.D., will present at the Cantor Virtual Global Healthcare Conference on Tuesday, September 15, 2020, at 9:20 a.m. ET. A live webcast of the presentation will be available on t

• Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model

  8/26/2020

  Stoke Therapeutics Announces Publication of Preclinical Data on STK-001 in the Journal Science Translational Medicine that Demonstrate Significant Improvements in Survival and Reductions in Seizure Frequency in a Dravet Syndrome Mouse Model STK-001 has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome A Phase 1/2a study of STK-001 in children and adolescents ages 2 to 18 years old is now underway

• Stoke Therapeutics Announces Appointment of Garry E. Menzel, Ph.D., to its Board of Directors

  8/17/2020

  Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced the appointment of Garry E. Menzel, Ph.D., to both its Board of Directors and Compensation Committee. “Garry brings more than 25 years of exe